NextCure (NXTC) Competitors $0.97 +0.02 (+2.11%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NXTC vs. JMAC, INMB, XFOR, ADVM, CRDL, DERM, ANRO, IMUX, SKYE, and MNOVShould you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Maxpro Capital Acquisition (JMAC), INmune Bio (INMB), X4 Pharmaceuticals (XFOR), Adverum Biotechnologies (ADVM), Cardiol Therapeutics (CRDL), Journey Medical (DERM), Alto Neuroscience (ANRO), Immunic (IMUX), Skye Bioscience (SKYE), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. NextCure vs. Maxpro Capital Acquisition INmune Bio X4 Pharmaceuticals Adverum Biotechnologies Cardiol Therapeutics Journey Medical Alto Neuroscience Immunic Skye Bioscience MediciNova Maxpro Capital Acquisition (NASDAQ:JMAC) and NextCure (NASDAQ:NXTC) are both small-cap unclassified companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations. Do analysts rate JMAC or NXTC? NextCure has a consensus price target of $4.00, indicating a potential upside of 312.37%. Given NextCure's stronger consensus rating and higher possible upside, analysts clearly believe NextCure is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NextCure 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in JMAC or NXTC? NextCure received 80 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformMaxpro Capital AcquisitionN/AN/ANextCureOutperform Votes8064.52% Underperform Votes4435.48% Does the media prefer JMAC or NXTC? In the previous week, NextCure had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for NextCure and 0 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.00 beat NextCure's score of -0.55 indicating that Maxpro Capital Acquisition is being referred to more favorably in the media. Company Overall Sentiment Maxpro Capital Acquisition Neutral NextCure Negative Is JMAC or NXTC more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat NextCure's return on equity.Company Net Margins Return on Equity Return on Assets Maxpro Capital AcquisitionN/A N/A N/A NextCure N/A -62.50%-53.67% Which has better valuation and earnings, JMAC or NXTC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxpro Capital AcquisitionN/AN/AN/AN/AN/ANextCureN/AN/A-$62.72M-$2.09-0.46 Do insiders and institutionals hold more shares of JMAC or NXTC? 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Comparatively, 13.3% of NextCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, JMAC or NXTC? Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, NextCure has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. SummaryNextCure beats Maxpro Capital Acquisition on 6 of the 11 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001." I put all the details together for you here — but please hurry. Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXTC vs. The Competition Export to ExcelMetricNextCurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.17M$6.57B$5.07B$9.08BDividend YieldN/A2.97%4.87%4.21%P/E Ratio-0.4610.5999.0517.15Price / SalesN/A195.041,121.17116.80Price / CashN/A57.1641.5237.88Price / Book0.245.104.754.78Net Income-$62.72M$151.51M$119.33M$225.60M7 Day Performance-10.19%-2.13%-1.86%-1.23%1 Month Performance-24.81%-3.14%11.40%3.07%1 Year Performance-13.39%11.53%30.26%16.48% NextCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXTCNextCure4.2163 of 5 stars$0.97+2.1%$4.00+312.4%-14.9%$27.17MN/A-0.4690Gap DownJMACMaxpro Capital AcquisitionN/A$8.34+7.8%N/A+837.6%$112.00MN/A0.002,021Gap DownINMBINmune Bio1.4803 of 5 stars$5.05+6.3%$20.00+296.0%-55.7%$111.97M$42,000.00-2.1810XFORX4 Pharmaceuticals4.3349 of 5 stars$0.65-2.6%$3.50+436.2%-16.4%$111.34MN/A-8.2280Gap DownADVMAdverum Biotechnologies4.1282 of 5 stars$5.33-0.7%$27.83+422.2%-40.0%$110.88M$1M-0.90190Analyst DowngradeNews CoveragePositive NewsCRDLCardiol Therapeutics2.2586 of 5 stars$1.33-0.4%$8.75+560.4%+44.0%$108.26M$60,000.00-3.4120Analyst ForecastAnalyst RevisionNews CoverageGap DownDERMJourney Medical2.5549 of 5 stars$5.04-1.0%$9.38+86.0%N/A$105.29M$79.18M-5.4190ANROAlto Neuroscience3.2602 of 5 stars$3.83flat$20.00+422.2%N/A$103.30M$210,000.000.00N/AGap UpIMUXImmunic2.9378 of 5 stars$1.15+1.3%$11.80+930.6%-20.6%$103.14MN/A-0.9270Positive NewsSKYESkye Bioscience2.0025 of 5 stars$3.38+0.9%$18.67+452.3%-10.6%$102.54MN/A0.0011News CoveragePositive NewsGap DownMNOVMediciNova2.1655 of 5 stars$2.09-0.5%$9.00+330.6%+43.7%$102.51M$1M-9.9510Analyst ForecastPositive News Related Companies and Tools Related Companies JMAC Competitors INMB Competitors XFOR Competitors ADVM Competitors CRDL Competitors DERM Competitors ANRO Competitors IMUX Competitors SKYE Competitors MNOV Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NXTC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NXTC Stock Alerts